Peripheral artery disease: Therapeutic advances

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 4, 2008, Pages 539-553

  Shamoun, Fadi ^a   Sural, Neethi ^a   Abela, George ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Claudication; Colistazol; Lipid; Medical therapy; Pentoxifylline; Peripheral arterial disease; Smoking

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOGENIC FACTOR; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BASIC FIBROBLAST GROWTH FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUPHENINE; CARNITINE; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; EW A 401; FIBROBLAST GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NAFTIDROFURYL; NIFEDIPINE; PAPAVERINE; PENTOXIFYLLINE; PLACEBO; PLASMID DNA; PROPIONYLCARNITINE; RAMIPRIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASODILATOR AGENT; WARFARIN;

ANKLE BRACHIAL INDEX; ATHEROSCLEROSIS; BLEEDING; BLOOD FLOW; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIARRHEA; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; ENZYME INHIBITION; EPIGASTRIC PAIN; EXERCISE; FOOT CARE; HEART PALPITATION; HIGH RISK PATIENT; HUMAN; INTERMITTENT CLAUDICATION; ISCHEMIA; LIFESTYLE MODIFICATION; LIMB ISCHEMIA; LIMB PAIN; MAGNETIC RESONANCE ANGIOGRAPHY; MONOTHERAPY; NAUSEA; NONHUMAN; PERIPHERAL ISCHEMIA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSICAL PERFORMANCE; PLETHYSMOGRAPHY; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; SKIN ALLERGY; SMOKING CESSATION; SYMPTOM; TACHYCARDIA; THROMBOSIS; UNSPECIFIED SIDE EFFECT; WALKING DIFFICULTY; DAILY LIFE ACTIVITY; KINESIOTHERAPY; PATHOPHYSIOLOGY; PERIPHERAL VASCULAR DISEASE; RISK FACTOR; UNITED STATES;

ACTIVITIES OF DAILY LIVING; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; EXERCISE THERAPY; HUMANS; INTERMITTENT CLAUDICATION; PERIPHERAL VASCULAR DISEASES; RISK FACTORS; UNITED STATES;

EID: 43049153321     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.4.539     Document Type: Review

References (122)

1. Hirsch AT et al. Perpheral arterial disease detection, awareness and treatment in primary care. JAMA 286, 1317-1324 (2001).
2. Wang JC, Criqui MH, Denenberg JO, McDermott MM, Golomb BA, Fronek A. Exertional leg pain in patients with and without peripheral arterial disease. Circulation 112(22), 3501-3508 (2005).
3. McDermott MM, Greenland P, Liu K et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA 286(13), 1599-606 (2001).
4. Norgren L, Hiatt WT, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J. Vasc. Surg. 45(Suppl. S), S5-S67 (2007).
5. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N. Engl. J. Med. 344(21), 1608 (2001).
6. Criqui MH, Langer RD, Fronek A et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N. Engl. J. Med. 326(6), 381-386 (1992).
7. Aboyans V, Lacroix P, Guilloux J et al. A predictive model for screening cerebrovascular disease in patient undergoing coronary artery bypass grafting. Interact. Cardiovasc. Thorac. Surg. 4(2), 90-95 (2005).
8. Aboyans et al. Subclinical peripheral arterial disease and incomplete ankle arteries are both long term prognostic factors in patients undergoing coronary artery bypass grafting. J. Am. Coll. Cardiol. 46(5), 815-820 (2005).
9. Cardiovascular Heart Study (CHS) Collaborative Research Group. Ankle - arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Circuiation 88(3), 837-845 (1993).
10. McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 87(2-3), 119-128 (1991).
11. Criqui MH, Langer RD, Fronek A et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N. Engl. J. Med. 326(6), 381-386 (1992).
12. Resnick et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation 109(6), 733-739 (2004).
13. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 110(6), 738-743 (2004).
14. Diehm C, Lange S, Darius H et al. Association of low ankle brachial index with high mortality in primary care. Eur. Heart J. 27(14), 1743-1749 (2006).
15. Peripheral Arterial Disease: ACC/AHA 2005 guidelines for the management of patients with (lower extremity, renal, mesenteric, and abdominal aortic): A collaborative report from the AAVS/SVS, SCAI, SVMB, SIR, and the ACC/AHA Task Force on Practice Guidelines.
16. Gardner AW, Skinner JS, Cantwell BW, Smith LK. Progressive vs single-stage treadmill tests for evaluation of claudication. Med. Sci. Sports Exerc. 23(4), 402-408 (1991).
17. Baum RA, Rutter CM, Sunshine JH. Multicenter Trial to evaluate vascular magnetic resonance angiography of the lower extremity. American College of Radiology Rapid Technology Assessment Group. JAMA 274(11), 875-880 (1995).
18. Prince MR, Chabra SG, Watts R et al. Contrast material travel times in patients undergoing peripheral MR angiography. Radiology 224(1), 55-61 (2002).
19. Rubin GD, Shiau MC, Leung AN, Kee ST, Logan LJ, Sofilos MC. Aorta and iliac arteries: single versus multiple detector-row helical CT angiography. Radiology 215(3), 670-676 (2000).
20. Rubin GD, Schmidt AJ, Logan LJ, Sofilos MC. Multi-detector row CT angiography of lower extremity arterial inflow and runoff: initial experience. Radiology 221(1), 146-158 (2001).
21. Gardener AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA 274(12), 975-980 (1995).
22. Regensteiner JG. Exercise in the treatment of claudication: assessment and treatment of functional impairment. Vasc. Med. 2(3), 238-242 (1997).
23. Robecr GG, Brandsma JW, van den Heuvel SP, Smit B, Oostendorp RA, Wittens CH. Exercise therapy for intermittent claudication: a review of the quality of randomized clinical trials and evaluation of predictive factors. Eur. J. Vasc. Endovasc. Surg. 15(1), 36-43 (1998).
24. McDermott MM, Liu K, Ferrucci L et al. Physical performance in peripheral arterial disease: a slower rate of decline in patients who walk more. Ann. Intern. Med. 144(1), 10-20 (2006).
25. Hiatt WR, Wolfel FE, Meier RH, Regensteiner JG. Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response. Circulation 90(4), 1866-1874 (1994).
26. Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT, Exercise training for claudication. N. Engl. J. Med. 347(24), 1941-1951 (2002).
27. Quick CR, Cotton LT. The measured effect of stopping smoking on intermittent claudication. Br. J. Surg. 69(Suppl.), S24--S26 (1982).
28. Willigendael EM, Teijink JA, Bartelink ML, Peters RJ, Büller HP, Prins MH. Smoking and the patency of lower extremity bypass grafts: a meta-analysis. J. Vasc. Surg. 42(1), 67-74 (2005).
29. Faulkner KW, House AK, Castleden WM. The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease. Med. J. Aust. 1(5), 217-219 (1993).
30. Girolami B, Bernardi E, Prins MH et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxyfylline, or nafronyl: a metaanalysis. Arch. Intern. Med. 159(4), 337-345 (1999).
31. Tsai ST, Cho HJ, Cheng HS et al. A randomized, placebo-controlled trial of varenicline, a selective α452 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin. Ther. 29(6), 1027-1039 (2007).
32. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am. J. Cardiol. 75(14), 894-903 (1995).
33. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes. (UKPDS 33). Lancet 352(9131), 837-853 (1998).
34. Giri J. McDermott MM, Greenland P et al. Statin use and functional decline in patients with and without peripheral arterial disease. J. Am. Coll. Cardiol. 47 (5), 998-1004 (2006).
35. Abbruzzese TA, Havens J, Belkin M et al. Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J. Vasc. Surg. 39(6), 1178-1185 (2004).
36. Poldermans D, Bax JJ, Kertai MD et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 107(14), 1848-1851 (2003).
37. Durazzo AE, Machado FS, Ikeoka DT et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J. Vasc. Surg. 39(5), 967-975 (2004).
38. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341(6), 410-418 (1999).
39. Mohler ER 3rd, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Cirrulation 108(12), 1481-1486 (2003).
40. Mondillo S, Ballo P, Barbati R et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterol patients with peripheral vascular disease. Am. J. Med. 114(5), 359-364 (2003).
41. Abela GS, Aziz K Cholesterol crystals cause mechanical damage to biological membranes: a proposed mechanism of plaque rupture and erosion leading to arterial thrombosis. Clin. Cardiol. 28(9), 413-420, (2005).
42. Abela GS, Aziz K. Cholesterol crystals rupture biological membranes and human plaques during acute cardiovascular events - a novel insight into plaque rupture by scanning electron microscopy. Scanning 28, 1-11 (2006).
43. Abela GS, Aziz K, Huang R, Delong J. Statins inhibit Cholesterol Crystallization and Prevent Perforation of Biological Membranes and Intima in Human Coronary Arteries of Patients with Acute Coronary Syndrome. J. Am. Coll. Card. 49, 358A (2007).
44. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329), 71-86 (2002).
45. CAPRIE Steering Committee. Arandomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348(9038), 1329-1339 (1996).
46. Bhatt DL, Flather MD, Hacke W et al. CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J. Am. Coll. Cardiol. 49(19), 1982-1988 (2007).
47. Collaborative analysis of long-term anticoagulant administration after acute myocardial infarction. An international anticoagulant review group. Lancet 1(7640), 203-209 (1970).
48. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N. Engl. J. Med. 323(3), 147-152, (1990).
49. The sixth report of the joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Arch. Intern. Med. 157(21), 2413-2446 (1997).
50. Ahimastos AA, Lawler A, Reid CM, Blombery PA, Kingwell BA. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Ann. Intern. Med. 144(9), 660-664 (2006).
51. Frohlich ED, Tarazi RC, Dustan HP. Peripheral arterial insufficiency: a complication of β-adrenergic blocking therapy. JAMA 208(13), 2471-2472 (1969).
52. Solomon SA, Ramsay LE, Yeo WW. Parnell L, Morris-Jones W. β blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. BMJ 303(6810), 1100-1104 (1991).
53. Radack K, Deck C. β adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: a meta analysis of randomized control trials. Arch. Intern. Med. 151(9), 1769-1776 (1991).
54. Yustif S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342(3), 145-153 (2000).
55. Feringa HH, van Waning VH, Bax JJ et al. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J. Am. Coll. Cardiol. 47(6), 1182-1187 (2006).
56. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N. Engl. J. Med. 338(15), 1042-1050 (2000).
57. Graham IM, Daly LE, Refsum HM et al. Plasma homocysteine as a risk factor for vascular diease. The European Concerted Action Project. JAMA 277(22), 1775-1781 (1997).
58. Westendorp IC, in't Veld BA, Grobbee DE et al. Hormone Replacement Therapy and peripheral arterial disease: The Rotterdam study. Arch. Inern. Med. 160(16), 2498-2502 (2000).
59. Regensteiner J, Ware JJ, McCarthy W et al. Effect of cilostazol on treadmill walking, community-based walking ability and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: metaanalysis of six randomized controlled trials. J. Am. Geriatr. Soc. 50(12), 1939-1946 (2002).
60. Dawson DL, Cutler BS, Hiatt WR et al. A comparison of cilostazol and pentoxyfylline for treating intermittent claudication. Am. J. Med. 109(7), 523-530 (2000).
61. Pratt C. Analysis of cilostazol safety database. Am. J. Cardiol. 87(12A), 28D-33D (2001).
62. Kim JY, Lee K, Shin M et al. Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention. Circ. J. 71(12), 1867-1872 (2007).
63. Samlaska CP, Winnfield EA. Pentoxyifylline. J. Am. Acad. Dermatol. 30(4), 603-621 (1994).
64. Jaff MR. Pharmacotherapy for peripheral arterial disease: emerging therapeutic options. Angiology 53(6), 627-633 (2002).
65. Carman TL, Fernandez BB Jr. Contemporary management of peripheral arterial disease: II. Improving walking distance and quality of life. Cleve. Clin. J. Med. 73(Suppl. 4), S38-S44 (2006).
66. Girolami B, Bernardi E, Prins MH et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch. Intern. Med. 159(4), 337-345 (1999).
67. Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. CMAJ 155(8), 1053-1059 (1996).
68. Lehert P, Comte S, Gamand S, Brown TM. Naftidrofuryl in intermittent claudication: a retrospective analysis. J. Cardiovasc. Pharmacol. 23(Suppl. 3), S48-S52 (1994).
69. Boccalon H, Lehert P, Mosnier M. Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication. Ann. Cardiol. Angeiol. (Paris) 50(3), 175-182 (2001).
70. Kieffer E, Bahnini A, Mouren X and Gamand S. A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS). Int. Angiol. 20(1), 58-65 (2001).
71. Spengel F, Clement D. Boccalon H, Liard F, Brown T, Lehert P. Findings of the Naftidrofuryl in Quality of Life (NIQOL) European study program. Int. Angiol. 21(1), 20-27 (2002).
72. Signorelli SS, Fatuzzo P, Rapisarda F et al. A randomized controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl L-carnitine in patients with peripheral arterial disease requiring hemodialysis. Drugs Aging 23(3), 263-270 (2006).
73. Brevetti G, Diehm C, Lambert D. European Multicenter studies on Propionyl-l-camitine in intermittent claudication. J. Am. Coll. Cardiol. 34(5), 1618-1624 (1999).
74. Hiatt WR, Regensteiner J, Creager M et al. Propionyl-l-carnitine improves exercise performance and functional status in patients with claudication. Am. J. Med. 110(8), 616-622 (2001).
75. Coffman J. Vasodilator drugs in peripheral vascular disease. N. Engl. J. Med. 301(3), 713-717 (1979).
76. De Backer T, Vander Stichele R, Bogaert M. Buflomedil for intermittent claudication. Cochrane Database Syst. Rev. (2001).
77. De Backer T, Vander Stichele R, Warie H, Bogaert M. Oral vasoactive medication in intermittent claudication: utile or futile? Eur. J. Clin. Pharmacol. 56(3), 199-206 (2000).
78. Rajagopalan S, Mohler EI, Lederman R et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108(16), 1933-1938 (2003).
79. Lederman R, Mendelsohn F, Anderson R et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (The TRAFFIC study): a randomized trial. Lancet 9323, 2053-2058 (2002).
80. Therapeutic Angiogenesis With Intramuscular NV1FGF in Patients With Critical Limb Ischemia (TALISMAN) 2006. Summary posted 3/12/2006. (2006).
81. Liu PQ, Rebar EJ, Zhang L et al. Regulation of an endogenous locus using a panel of designed zinc finger proteins targeted to accessible chromatin regions. Activation of vascular endothelial growth factor A. J. Biol. Chem. 276, 11323-11334 (2001).
82. Dai Q, Huang J, Klitzman B et al. Engineered zinc finger-activating vascular endothelial growth factor transcription factor plasmid DNA induces therapeutic angiogenesis in rabbits with hindlimb ischemia. Circulation 110, 2467-2475 (2004).
83. Rebar EJ, Huang Y, Hickey R et al. Induction of angiogenesis in a mouse model using engineered transcription factors. Nat. Med. 8, 1427-1432 (2002).
84. Xie D, Li Y, Reed EA et al. An engineered vascular endothelial growth factor-activating transcription factor induces therapeutic angiogenesis in ApoE knockout mice with hindlimb ischemia. J. Vasc. Surg. 44, 166-175 (2006).
85. Rajagopalan S, Olin J, Deitcher S et al. Use of a constitutively active hypoxia-inducible factor-1α transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience. Circulation 115, 1234-1243 (2007).
86. Yamakawa M, Liu LX, Date T et al. Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. Circ. Res. 93, 664-673 (2003).
87. Murohara T, Ikeda H, Duan J et al., Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J. Clin. Invest. 105, 1527-1536 (2000).
88. Kalka, C, Masuda H, Takahashi T et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc. Natl Acad. Sci. USA 97 3422-3427 (2000).
89. Mikroulis D, Papanas N, Maltezos E, Bougioukas G. Angiogenic growth factors in the treatment of peripheral arterial disease. Curr. Vasc. Pharmacol. 5(3), 195-209 (2007).
90. Tateishi-Yuyama E, Matsubara H, Murohara T et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 360, 427-435 (2002).
91. Boger RH, Bode-Boger SM, Thiele W, Creutzig A, Alexander K, Frolich JC. Restoring vascular nitric oxide formation by L-Arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J. Am. Coll. Cardiol. 32(5), 1336-1344 (1998).
92. Maxwell AJ, Anderson BE and Cooke JP. Nutritional therapy for peripheral arterial disease: a souble blind, placebo controlled, randomized trial of HeartBar. Vasc. Med. 5(1), 11-19 (2000).
93. Hiatt WR, Klepack E, Nehler M et al. The effect of inhibition of acyl coenzyme A-cholesterol acyltransferase (ACAT) on exercise performance in patients with peripheral arterial disease. Vasc. Med. 9(4), 271-277 (2004).
94. Norgren L, Jawien A, Matyas L, Rieger H, Arita K. The European MCI-9042 Study Group. Sarpogrelate, a 5-HT2A receptor antagonist in intermittent claudication. A Phase II European Study. Vasc. Med. 11(2), 75-83 (2006).
95. Miyazaki M, Higashi Y, Goto C et al. Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease. J. Cardiovasc. Pharmacol. 49(4), 221-227 (2007).
96. Thulesius O, Lundwall J, Kroese A et al. Ketanserin in intermittent claudication: effect on walking distance, blood pressure and cardiovascular complications. J. Cardiovasc. Pharmacol. 9(6), 728-733 (1987).
97. Nehler MR, Brass EP, Anthony R et al. Circulase investigators. Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes. J. Vasc. Surg. 45(5), 953-960 (2007).
98. Belch J, Bell P, Creissen D et al. Randomised, placebo-controlled double blind study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication. Circulation 95(9), 2298-2303 (1997).
99. Creager M, Dzau V and Loscalzo J. Vascular Medicine - A Companion to Braunwald's Heart Disease. WB Saunders (2006).
100. Lievre M, Morand S, Besse B, Fiessinger J, Boissel J. Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittents (BERCI) Research Group. Circulation 102(4), 426-431 (2000).
101. Mohler ER 3rd, Hiatt WR. Olin J, Wade M, Jeffs R, Hirsch A. Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin 12 analogue: a double-blinded, randomized controlled trial. J. Am. Coll. Cardiol. 41(10), 1679-1686 (2003).
102. Delis KT, Nicolaides AN, Wolfe JH, Stansby G. Improving walking ability and ankle brachial pressure indices in symptomatic peripheral vascular disease with intermittent pneumatic compression: a prospective controlled study with one-year followup. J. Vasc. Surg. 31(4), 650-651 (2000).
103. Gaskell P, Parrott JC. The effect of a mechanical venous pump on the circulation of the feet in the presence of arterial obstruction. Surg. Gynecol. Obstet. 146(4), 583-592 (1978).
104. Morgan RH, Carolan G, Saila JV et al. Arterial flow enhancement by impulse compression. Vasc. Surg. 25, 8-15 (1991).
105. Delis KT, Labropoulos N, Nicolaides AN, Glenville B, Stansby G. The effect of intermittent pneumatic foot compression on popliteal artery hemodynamics. Eur. J. Vasc. Endovasc. Surg. 19(3), 270-278 (2000).
106. Delis KT, Azizi ZA, Stevens RJ, Wolfe JH, Nicolaides AN. Determining the optimum intermittent pneumatic compression stimulus for lower limb venous emptying using direct pressure measurements. Eur. J. Vasc. Endovasc. Surg. 19(3), 261-270 (2000).
107. Delis KT, Nicolaides AN, Wolfe JH, Stansby G. Improving walking ability and ankle brachial pressure indices in symptomatic peripheral vascular disease with intermittent pneumatic compression: a prospective controlled study with one-year follow-up. J. Vasc. Surg. 31(4), 650-651 (2000).
108. Laurora G, Ambrosoli L, Cesarone MR et al. Treatment of intermittent claudicaiton with defibrotide or mesoglycan. A double blind study. Panminerva Med. 36(2), 83-86 (1994).
109. Strano A, Fareed J, Sabba C et al. A double blind multicenter, placebo-controlled, dose comparison study of orally administered defibrotide: preliminary results in patients with peripheral arterial disease. Semin. Thromb. Hemost. 17(Suppl. 2), 228-234 (1991).
110. Violi F, Marubini E, Coccheri S, Nenci GG. Improvement of walking distance by defibrotide in patients with intermittent claudication - results of a randomized, placebo-controlled study the DICLIS study). Defibrotide Intermittent Claudication Italian Study. Thromb. Haemost. 83(5), 672-677 (2000).
111. Niezgoda JA, Mewissen M. The management of lower extremity wounds complicated by acute arterial insufficiency and ischemia. Ostomy Wound Manage. 50(5A Suppl.), 1-11 (2004).
112. Vincenzo S, Kyventidis T. Epidural spinal cord stimulation in lower limb ischemia. Acta. Neurochir. Suppl. 97(Pt 1), 253-258 (2007).
113. Ouriel K. Peripheral arterial disease. Lancet 358, 1257 (2001).
114. Pell JP. Impact of intermittent claudication on quality of life. The Scottish Vascular Audit Group. Eur. J. Vasc. Endovasc. Surg. 9, 469 (1995).
115. Currie IC, Wilson YG, Baird RN et al. Treatment of intermittent claudication: The impact on quality of life. Eur. J. Vasc. Endovasc. Surg. 10, 356 (1995).
116. Zannetti S, L'Italien GJ, Cambria RP. Functional outcome after surgical treatment for intermittent claudication. J. Vasc. Surg. 24, 65 (1996).
117. Matsi, PJ, Manninen, HI, Vanninen, RL et al. Femoropopliteal angioplasty in patients with claudication: Primary and secondary patency in 140 limbs with 1-3 year follow-up. Radiology 191, 727 (1994).
118. Capek, P, McLean, GK, Berkowitz, HD. Femoropopliteal angioplasty. Factors influencing long-term success. Circulation 83, 170 (1991).
119. Taylor LM Jr, Porter JM. Clinical and anatomic considerations for surgery in femoropopliteal disease and the results of surgery. Circulation 83(Suppl.), I-63-I-69 (1991).
120. Slovut DP and Demaioribus CA. Hybrid revascularization using Silverhawk atherectomy and infrapopliteal bypass for limbs. Ann. Vasc. Surg. 21(6), 796-800 (2007).
121. Zeller T, Sixt S, Schwarzwälder U et al. Two-year results after directional athcrectomy of infrapopliteal arteries with the SilverHawk device. J. Endovasc. Ther. 14(2), 232-240 (2007).
122. Abela GS. Innovations in laser applications in the cardiovascular field. Keio J. Med. 42(4), 164 (1993).